Immune globulin - CSL Behring

Drug Profile

Immune globulin - CSL Behring

Alternative Names: Beriglobin P; Berirab P; Carimune NF; Gamma Venin P; Hizentra; IgNextGen 10%; IgPro10; IgPro16; IgPro20; Immune Globulin Subcutaneous [Human] 20% Liquid; IVIG 10% -CSL Behring; Privigen; Redimune; Redimune NF liquid; Rhesogamma P; Rhophylac; Sandoglobulin; Sandoglobulin NF liquid; Tetagam P; Varicellon; Venimmun N; Vivaglobin

Latest Information Update: 26 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Developer Assistance Publique Hopitaux de Paris; CSL Behring; Georgetown University; Rigshospitalet; University of Oxford
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Haemolytic disease of newborn; Hepatitis A; Hepatitis B; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome; Rabies; Tetanus; Varicella zoster virus infections
  • Phase III Encephalitis; Renal transplant rejection
  • Phase II Scleroderma; Skin and soft tissue infections
  • Phase I Pelvic inflammatory disorders; Spinal cord injuries
  • No development reported Motor neuron disease; Systemic lupus erythematosus

Most Recent Events

  • 20 Jun 2018 Phase-I clinical trials in Pelvic inflammatory disorders (In adults, In adolescents) in USA (SC) (EudraCT2016-003798-16)
  • 21 Apr 2018 Pooled efficacy and adverse events data from the phase III PRIMA and PATH trials in Chronic inflammatory demyelinating polyradiculoneuropathy presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
  • 16 Mar 2018 Launched for Chronic inflammatory demyelinating polyradiculoneuropathy in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top